Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1.

Kilickap, Saadettin; Baramidze, Ana; Sezer, Ahmet; Özgüroğlu, MUSTAFA; Gumus, Mahmut; Bondarenko, Igor; Gogishvili, Miranda; Nechaeva, Marina; Schenker, Michael; Cicin, Irfan; Fuang, Ho; Kulyaba, Yaroslav; Zyuhal, Kasimova; Scheusan, Roxana-Ioana; Garassino, Marina; Li, Yuntong; Zhu, Cong; Kaul, Manika; Perez, Javier; Seebach, Frank; Lowy, Israel; Pouliot, Jean-Francois; Kim, Eric; Magnan, Heather

doi:10.1016/j.jtho.2025.03.033

Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1.

Kilickap S., Baramidze A., Sezer A., Özgüroğlu M., Gumus M., Bondarenko I., ...Daha Fazla

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, cilt.20, ss.941-954, 2025 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 20
Basım Tarihi: 2025
Doi Numarası: 10.1016/j.jtho.2025.03.033
Dergi Adı: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, MEDLINE
Sayfa Sayıları: ss.941-954
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır